Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genscript Biotech's Enterprise Value is €2,753.3 Mil.
Genscript Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €208.9 Mil. Therefore, Genscript Biotech's EV-to-FCF for today is 13.18.
The historical rank and industry rank for Genscript Biotech's EV-to-FCF or its related term are showing as below:
STU:G51'
s EV-to-FCF Range Over the Past 10 Years
Min: -632.81 Med: -14.43 Max: 187.78
Current: 12.98
During the past 12 years, the highest EV-to-FCF of Genscript Biotech was 187.78. The lowest was -632.81. And the median was -14.43.
STU:G51's EV-to-FCF is ranked better than 54.03% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs STU:G51: 12.98
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genscript Biotech's PE Ratio (TTM) for today is calculated as:
Genscript Biotech's share price for today is €1.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.219.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genscript Biotech EV-to-FCF Related Terms
Genscript Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genscript Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's EV-to-FCF falls into.
Genscript Biotech's current Enterprise Value is €2,753.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €208.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (STU:G51) has a EV-to-FCF of 13.18 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #154 out of 335 companies in the Biotechnology industry, placing it in the top 46%.
Is Genscript Biotech's EV-to-FCF too high?
Genscript Biotech's current EV-to-FCF is 13.18. The Biotechnology industry median EV-to-FCF is 15.51. Genscript Biotech's value of 13.18 is 15% below this industry median. Based on the distribution chart, Genscript Biotech ranks #154 out of 335 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #154 out of 335 companies for EV-to-FCF. This puts Genscript Biotech in the upper half of its industry. The industry median EV-to-FCF is 15.51. Genscript Biotech's value of 13.18 is 15% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current EV-to-FCF of 13.18 is 15% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current EV-to-FCF is 13.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (STU:G51) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.25, compared to a current price of €1.42 — trading 36.9% below its estimated fair value. The current EV-to-FCF is 13.18 and 15% below the Biotechnology industry median of 15.51. Genscript Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Genscript Biotech (STU:G51), the current EV-to-FCF is 13.18 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (STU:G51) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of €1.42 is trading 36.9% below its estimated GF Value™ of €2.25.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for STU:G51:
EV-to-FCF: 13.18
GF Value™: €2.25 vs. price of €1.42 (36.9% below fair value)
Industry Position: 15% below the Biotechnology median (#154 of 335)
No single metric tells the full story. See the STU:G51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
67GF Score
Get the complete analysis for STU:G51
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:G51 has been successfully added to your 
